CLINICAL TRIALS PROFILE FOR EXTRANEAL
✉ Email this page to a colleague
All Clinical Trials for Extraneal
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00368641 ↗ | Heart Failure and Peritoneal Ultrafiltration | Terminated | Baxter Healthcare Corporation | Phase 2 | 2006-08-01 | The objective of the study is to determine if the addition of peritoneal ultrafiltration to standard therapy in treatment-resistant severe heart failure patients will improve fluid balance and functional capacity such that they will spend less time in the hospital and have an improved ambulatory quality of life in comparison to patients who remain on standard therapy alone. |
| NCT00397358 ↗ | Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients | Withdrawn | Baxter Healthcare Corporation | Phase 4 | 2006-11-01 | This is a Phase IV study evaluating triglyceride levels in peritoneal dialysis patients. |
| NCT00567398 ↗ | IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients | Completed | Baxter Healthcare Corporation | Phase 3 | 2008-04-01 | Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD)and Automated Peritoneal Dialysis (APD) patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the HbA1c levels. Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs Dianeal) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and Quality of Life. In a subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs Dianeal only) on abdominal fat and left ventricular (LV) structure and function will be assessed. |
| NCT00567489 ↗ | IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients | Completed | Baxter Healthcare Corporation | Phase 4 | 2008-01-01 | Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the HbA1c levels. Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and Quality of Life. In a subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs Dianeal only) on abdominal fat and left ventricular (LV) structure and function will be assessed. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Extraneal
Condition Name
Clinical Trial Locations for Extraneal
Trials by Country
Clinical Trial Progress for Extraneal
Clinical Trial Phase
Clinical Trial Sponsors for Extraneal
Sponsor Name
